Document Detail


Quantitative MRI Establishes the Efficacy of PI3K Inhibitor (GDC-0941) Multi-Treatments in PTEN-deficient Mice Lymphoma.
MedLine Citation:
PMID:  22287727     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
MATERIALS AND METHODS: Using 3D MRI, B-cell follicular lymphoma growth was quantified in a Pten(+/-)Lkb1(+/hypo) mouse line, before, during and after repeated treatments with a PI3K inhibitor GDC-0941 (75 mg/kg).
RESULTS: Mean pre-treatment linear tumour growth rate was 16.5±12.8 mm(3)/week. Repeated 28-day GDC-0941 administration, with 21 days 'off-treatment', induced average tumour regression of 41±7%. Upon cessation of the second treatment (which was not permanently cytocidal), tumours re-grew with an average linear growth rate of 40.1±15.5 mm(3)/week. There was no evidence of chemoresistance.
CONCLUSION: This protocol can accommodate complex dosing schedules, as well as combine different cancer therapies. It reduces biological variability problems and resulted in a 10-fold reduction in mouse numbers compared with terminal assessment methods. It is ideal for preclinical efficacy studies and for phenotyping molecularly characterized mouse models when investigating gene function.
Authors:
Stephan Wullschleger; Juan M García-Martínez; Suzanne L Duce
Related Documents :
9731427 - A new fuzzy logic based image enhancement.
16484347 - Hepatic metastases: detection with multi-detector row ct, spio-enhanced mr imaging, and...
7820127 - Skin penetration enhancement of acyclovir by prodrug-enhancer combination.
8743997 - Prognostic value of contrast-enhanced magnetic resonance imaging in brainstem gliomas.
16567437 - Assessment of the therapeutic response of hepatocellular carcinoma treated with transca...
1345747 - Basics of the magnetic resonance phenomenon.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Anticancer research     Volume:  32     ISSN:  1791-7530     ISO Abbreviation:  Anticancer Res.     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-01-30     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8102988     Medline TA:  Anticancer Res     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  415-20     Citation Subset:  IM    
Affiliation:
Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K. s.duce@dundee.ac.uk.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Tumor interstitial fluid as modulator of cancer inflammation, thrombosis, immunity and angiogenesis.
Next Document:  Polymorphisms of the Epidermal Growth Factor Receptor (EGFR) and Survival in Patients with Advanced ...